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A bs tr ac t
Background
Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent 
stroke. In addition, inhibition of the renin–angiotensin system in high-risk patients 
reduces the rate of subsequent cardiovascular events, including stroke. However, the 
effect of lowering of blood pressure with a renin–angiotensin system inhibitor soon 
after a stroke has not been clearly established. We evaluated the effects of therapy 
with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke.
Methods
In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, 
we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to re-
ceive placebo. The primary outcome was recurrent stroke. Secondary outcomes were 
major cardiovascular events (death from cardiovascular causes, recurrent stroke, 
myocardial infarction, or new or worsening heart failure) and new-onset diabetes.
Results
The median interval from stroke to randomization was 15 days. During a mean follow-
up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan 
group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group 
and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in 
the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P = 0.23). Major 
cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 
1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; 
P = 0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the 
placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10).
Conclusions
Therapy with telmisartan initiated soon after an ischemic stroke and continued for 
2.5 years did not significantly lower the rate of recurrent stroke, major cardiovas-
cular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.)
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Stroke is the second most frequent cause of death in the world and is respon-sible for about 5 million deaths each year.1 
An additional 15 million persons have nonfatal 
strokes, with about a third having disabling con-
sequences. Elevated blood pressure is the stron-
gest risk factor for stroke, and lowering of blood 
pressure, especially in patients with substantially 
elevated levels (e.g., systolic pressure, >160 mm Hg), 
reduces the risk of stroke.2 After a stroke, lower-
ing blood pressure with a combination of an an-
giotensin-converting–enzyme (ACE) inhibitor and 
a diuretic reduced rates of recurrent stroke in the 
Perindopril Protection against Recurrent Stroke 
Study (PROGRESS).3
Several other trials have raised the possibility 
of an additional mechanism, independent of 
blood-pressure lowering, by which blockers of 
the renin–angiotensin system may be beneficial 
in patients with stroke.4 In the Heart Outcomes 
Prevention Evaluation (HOPE) trial, ACE-inhibi-
tor therapy reduced the rate of stroke in patients 
with previous cardiovascular events or high-risk 
diabetes despite only a small reduction in blood 
pressure, with consistent results in those with 
and those without previous strokes.5,6 Another 
recent trial7 demonstrated that eprosartan re-
duced the number of recurrent strokes and tran-
sient ischemic attacks (but not the proportion of 
patients with stroke), as compared with a calcium-
channel blocker, in patients with previous stroke, 
despite a similar reduction in blood pressure. In 
one small study, an angiotensin-receptor blocker 
(ARB) that was started soon after a stroke re-
duced the rates of death and cardiovascular events 
despite no blood-pressure reduction.8
In these studies, the majority of patients were 
enrolled several months or years after a stroke, 
and the potential benefit of the use of renin–
angiotensin system blockers soon after a stroke 
was not clearly established. We therefore evalu-
ated whether therapy with telmisartan, an ARB, 
given at a dose of 80 mg per day, could reduce 
the risk of stroke when initiated within 4 months 
after a stroke and continued for 2.5 years.
Me thods
Study Protocol 
Details of the trial protocol have been published 
previously.9 Patients were from 695 centers in 35 
countries and had recently had an ischemic stroke. 
We used a two-by-two factorial design to compare 
four regimens: a combination of acetylsalicylic 
acid (aspirin) and extended-release dipyridamole, 
as compared with clopidogrel, and telmisartan 
as compared with placebo. All patients also re-
ceived medications for blood-pressure control at 
the discretion of the investigators. The trial was 
approved by the ethics committee or institutional 
review board at each national or local site. This 
report focuses on the component of the trial com-
paring telmisartan with placebo.
Study Design
The trial was sponsored by Boehringer Ingelheim, 
with additional support from Bayer Schering 
Pharma and GlaxoSmithKline, and was designed 
by the steering committee, which included repre-
sentatives of the sponsor. Data were collected by 
investigators at each site. The final statistical anal-
yses were conducted simultaneously by indepen-
dent statisticians at the Medical University of South 
Carolina, who provided data and interim analysis 
reports to the data and safety monitoring com-
mittee, and the statisticians from Boehringer In-
gelheim. After the database was locked, a confir-
matory analysis was performed by the sponsor. 
Minor discrepancies between the two data analy-
ses were resolved by mutual agreement. The three 
principal academic investigators had full access 
to the data, wrote the manuscript with input from 
all the coauthors, and vouch for the accuracy and 
completeness of the data and the analyses.
Eligibility
According to the initial protocol, patients 55 years 
of age or older who had had an ischemic stroke 
less than 90 days before randomization and whose 
condition was stable were eligible to participate 
in the study. The diagnosis of ischemic stroke 
was defined as a new focal neurologic deficit of 
cardiovascular origin persisting for more than 24 
hours. Patients whose symptoms persisted for 
less than 24 hours could be included if they had 
evidence of a recent ischemic stroke on computed 
tomography or magnetic resonance imaging. Af-
ter about 6000 patients had been enrolled, the 
protocol was modified to allow the inclusion of 
younger patients (50 to 54 years) and those who 
had had less recent strokes (within 90 to 120 
days) if they also had at least two additional risk 
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factors. Patients were excluded if they had had a 
primary hemorrhagic stroke, severe disability af-
ter the qualifying stroke, contraindications to one 
of the study antiplatelet agents, or other factors 
making them unsuitable for randomization.9 All 
participants provided written informed consent.
Randomization, Treatment, and Follow-up
Eligible and consenting patients underwent ran-
domization with the use of a central telephone 
system to receive either a twice-daily fixed-dose 
combination of aspirin (25 mg) plus extended-
release dipyridamole (200 mg) or once-daily 
clopidogrel (75 mg) and either once-daily telmi-
sar tan (80 mg) or placebo. Patients were evalu-
ated at the time of hospital discharge or in a 
clinic visit at 1 week and then at 1, 3, and 6 
months; they were then evaluated every 6 months. 
Interim telephone calls were scheduled halfway 
between clinic visits.
Outcome Events
The primary outcome was recurrent stroke of any 
type. The two secondary outcomes were major 
cardiovascular events (death from cardiovascular 
causes, myocardial infarction, recurrent stroke, or 
worsening or new heart failure) and new-onset 
diabetes. A central committee adjudicated the pri-
mary outcome and the first of the secondary out-
comes, whereas the diagnosis of new-onset dia-
betes was based on center reports.
Statistical Analysis
The trial was initially designed to enroll 15,500 
patients, a sample size that was considered suf-
ficient to accrue 2170 patients with recurrent 
stroke during a 4-year trial. On the basis of this 
assumption, the trial would have a power of more 
than 99% to detect a relative risk reduction of 
25% in the telmisartan group, as compared with 
the placebo group, given the evidence at the 
time.6,10 However, despite a subsequent increase 
in sample size to more than 20,000 patients and 
a 6-month extension of the trial, only 1715 pa-
tients with recurrent stroke were projected. This 
revised event rate provided a power of 91% to 
detect a relative risk reduction of 15% in the tel mi-
sartan group, as compared with the placebo 
group.
The primary analysis was the time to recur-
rent stroke. A Cox proportional-hazards regres-
sion model with baseline age, diabetes status, 
ACE-inhibitor use, and modified Rankin Scale as 
covariates was the prespecified model intended 
to be used for the analysis of outcomes. However, 
the assumption of proportional hazards was not 
satisfied, and we therefore explored whether the 
treatment effect varied according to time (after an 
inspection of the Kaplan–Meier curves), with ad-
ditional analyses describing the results separately 
within and beyond 6 months. All analyses of the 
outcomes were conducted under the intention-to-
treat principle with the use of a time-to-event ap-
proach and included all randomized patients.
Subgroup analyses for the primary outcome 
and for major cardiovascular events were evalu-
ated with the use of tests for interaction for pre-
specified baseline features. These included the use 
of ACE inhibitors, systolic blood pressure, history 
of diabetes mellitus, and a stroke risk score gen-
erated from the overall data of the trial, which 
included age, sex, physical activity level, baseline 
systolic blood pressure, history of hypertension, 
diabetes status, previous myocardial infarction, 
atrial fibrillation, peripheral arterial disease, and 
stroke before qualifying event (for details, see the 
Supplementary Appendix, available with the full 
text of this article at www.nejm.org).
R esult s
Patients
From September 11, 2003, to July 14, 2006, a to-
tal of 20,332 patients were enrolled in the trial. 
Of these patients, 10,146 were assigned to receive 
telmisartan and 10,186 to receive placebo. Base-
line characteristics of the patients are shown in 
Table 1. The mean blood pressure at entry was 
144.1 mm Hg systolic and 83.8 mm Hg diastolic. 
About 42% of the patients had an ethnic back-
ground other than white European, 25% had had 
previous transient ischemic attacks (TIA) or stroke 
before the qualifying stroke, 19% had evidence 
of atherosclerosis in other vascular beds, 28% 
had diabetes, 74% had a history of hypertension, 
and 57% were current or previous smokers; 37% 
of patients were receiving an ACE inhibitor. The 
majority of patients had recently had a qualifying 
stroke caused by occlusion of a small artery, and 
24% were at least moderately disabled (score on 
Rankin Scale, ≥3). The time from stroke to ran-
domization was 10 days or less among 8087 pa-
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tients (40%), 11 to 30 days among 5887 patients 
(29%), and more than 30 days among 6314 pa-
tients (31%). The median interval from stroke to 
randomization was 15 days.
Follow-up and Adherence
The mean duration of follow-up was 30 months 
(range, 18 to 52). A total of 125 patients (51 in the 
telmisartan group and 74 in the placebo group) 
(0.6%) were lost to follow up.
Among patients in the telmisartan group, 7627 
of 9825 patients (77.6%) were receiving the study 
drug at 1 year, 5453 of 7403 (73.7%) at 2 years, 
and 1736 of 2542 (68.3%) at 3 years, with 175 
(1.7%) receiving a nonstudy ARB at 1 year and 
233 (2.3%) at the penultimate visit. In the placebo 
group, 7916 of 9856 patients (80.3%) were receiv-
ing a study drug at 1 year, 5702 of 7439 (76.7%) 
at 2 years, and 1803 of 2545 (70.8%) at 3 years, 
with 219 (2.2%) receiving a nonstudy ARB at 1 year 
and 254 (2.5%) at the penultimate visit.
By the end of the study, the use of diuretics, 
ACE inhibitors, calcium-channel blockers, and 
beta-blockers was more frequent in the placebo 
group than in the telmisartan group, with the 
comparative rates as follows: diuretics, 22.6% in 
Table 1. Characteristics of the Patients.*
Variable Telmisartan (N = 10,146) Placebo (N = 10,186)
Age — yr 66.1±8.6 66.2±8.6
Blood pressure — mm Hg 144.1±16.4/83.8±10.5 144.2±16.7/83.8±10.6
Heart rate — beats/min 73.2±11.7 73.1±11.7
Body-mass index 26.8±5.0 26.8±5.0
Female sex — no. (%) 3619 (35.7) 3691 (36.2)
Ethnic group — no. (%)†
Chinese 1843 (18.2) 1823 (17.9)
South Asian 849 (8.4) 863 (8.5)
Other Asian 640 (6.3) 642 (6.3)
African 407 (4.0) 409 (4.0)
White/European 5827 (57.4) 5870 (57.6)
Native Latin 494 (4.9) 496 (4.9)
Other 86 (0.8) 83 (0.8)
Clinical history — no. (%)
Previous stroke or TIA 2486 (24.5) 2511 (24.7)
Atherosclerotic disease‡ 1898 (18.7) 2053 (20.2)
Atrial fibrillation 266 (2.6) 274 (2.7)
Hypertension 7510 (74.0) 7538 (74.0)
Diabetes mellitus 2840 (28.0) 2903 (28.5)
Hyperlipidemia 4735 (46.7) 4758 (46.7)
Left ventricular hypertrophy 1577 (15.5) 1590 (15.6)
Smoking status — no. (%)
Current 2151 (21.2) 2157 (21.2)
Past 3703 (36.5) 3649 (35.8)
Use of medication at baseline — no. (%)
Statin 4742 (46.7) 4872 (47.8)
ACE inhibitor 3737 (36.8) 3782 (37.1)
Diuretic 2093 (20.6) 2168 (21.3)
Calcium-channel blocker 2487 (24.5) 2473 (24.3)
Beta-blocker 2096 (20.7) 2135 (21.0)
Index stroke ≤10 days before randomization — no. (%) 4021 (39.6) 4066 (39.9)
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the telmisartan group and 28.2% in the placebo 
group; ACE inhibitors, 28.4% and 33.9%, respec-
tively; calcium-channel blockers, 26.5% and 30.9%, 
respectively; and beta-blockers, 22.3% and 25.4%, 
respectively. 
Blood Pressure, Creatinine, and Potassium
At 1 month, there was a reduction in average sys-
tolic blood pressure of 8.3 mm Hg in the telmis-
artan group, as compared with a reduction of 2.9 
mm Hg in the placebo group (between-group 
difference, 5.4 mm Hg) (Fig. 1 in the Supplemen-
tary Appendix). However, at 1 year, the between-
group difference in systolic blood pressure favor-
ing telmisartan had narrowed to 4.0 mm Hg, with 
an average difference of only 3.8 mm Hg between 
the two groups throughout the study. Although 
the between-group difference in diastolic blood 
pressure favoring telmisartan was 2.9 mm Hg at 
1 month, it narrowed to 2.2 mm Hg at 1 year and 
to 1.6 mm Hg by the end of the study, with an 
average between-group difference favoring tel-
mi sartan of 2.0 mm Hg.
In the two groups, the mean creatinine level 
at baseline was 1.0 mg per deciliter (88 μmol per 
liter), and the mean potassium level was 4.1 mmol 
per liter. At 1 month, the mean creatinine level 
increased by 0.06 mg per deciliter (5 μmol per 
liter) in the telmisartan group and 0.09 mg per 
deciliter (8 μmol per liter) in the placebo group. 
At the same time, the mean potassium level in-
creased by 0.22 mmol per liter in the telmisartan 
group and 0.13 mmol per liter in the placebo 
group. At 1 month, the proportion of patients with 
a creatinine level of more than 1.5 mg per deci-
liter (133 μmol per liter) was similar in the tel mi-
sartan group and the placebo group (6.2% and 
5.8%, respectively), whereas the proportion of 
patients with a potassium level of more than 5.5 
mmol per liter was significantly higher in the 
telmisartan group than in the placebo group (1.6% 
and 0.8%, respectively; P<0.001).
Adverse Events
Adverse events leading to discontinuation of a 
study medication are listed in Table 2. The listed 
adverse events were selected on the basis of med-
ical interest and the mechanism of action of tel-
Table 1. (Continued.)
Variable Telmisartan (N = 10,146) Placebo (N = 10,186)
TOAST classification
Large-artery atherosclerosis 2907 (28.7) 2898 (28.5)
Cardioembolism 187 (1.8) 182 (1.8)
Small-artery occlusion 5283 (52.1) 5295 (52.0)
Other 1769 (17.4) 1811 (17.8)
Score on modified Rankin Scale — no. (%)§
0 1420 (14.0) 1433 (14.1)
1 3732 (36.8) 3848 (37.8)
2 2555 (25.2) 2526 (24.8)
3–5 2439 (24.0) 2379 (23.4)
Baseline NIH Stroke Scale — no. (%)¶
0–1 4044 (39.9) 4047 (39.7)
2–3 2937 (28.9) 3049 (29.9)
4–5 1740 (17.1) 1612 (15.8)
6–14 1350 (13.3) 1397 (13.7)
>14 72 (0.7) 79 (0.8)
* Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height 
in meters. ACE denotes angiotensin-converting enzyme, NIH National Institutes of Health, TIA transient ischemic at-
tack, and TOAST Trial of ORG 10172 in Acute Stroke Treatment. 
† Ethnic group was self-reported. The term Native Latin refers to Latin American ethnic background.
‡ P = 0.05.
§ The modified Rankin Scale score ranges from 0 to 6, with higher scores indicating greater severity.
¶ The NIH Stroke Scale ranges from 0 to 42, with higher scores indicating greater severity.
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mi sartan. Hypotension or syncope led to study 
discontinuation significantly more often in the 
telmisartan group than in the placebo group.
Primary and Secondary Outcomes
There was no significant interaction between the 
results of the antiplatelet comparison and the com-
parison between telmisartan and placebo (P = 0.35 
for interaction). The primary outcome of first re-
current stroke occurred in 880 patients (8.7%) in 
the telmisartan group, as compared with 934 pa-
tients (9.2%) in the placebo group (hazard ratio, 
0.95; 95% confidence interval [CI], 0.86 to 1.04; 
P = 0.23) (Fig. 1 and Table 3). This nonsignificant 
difference was consistent across various subtypes 
of stroke. Post hoc exploratory analyses indicated 
that the number of patients who had a recurrent 
stroke during the first 6 months was 347 (3.4%) 
in the telmisartan group, as compared with 326 
(3.2%) in the placebo group (hazard ratio, 1.07; 
95% CI, 0.92 to 1.25). After 6 months, 533 pa-
tients (5.3%) had a recurrent stroke in the tel mi-
sartan group, as compared with 608 (6.0%) in 
the placebo group (hazard ratio, 0.88; 95% CI, 
0.78 to 0.99). The difference in effects that were 
observed during the two periods was significant 
(P = 0.04 for interaction).
The number of patients with a major cardio-
vascular event was 1367 (13.5%) in the telmisar-
tan group, as compared with 1463 (14.4%) in the 
placebo group (hazard ratio, 0.94; 95% CI, 0.87 
to 1.01) (Fig. 2A and Table 3). Post hoc explor-
atory analyses indicated that the number of such 
events occurring within 6 months after random-
ization was 474 (4.7%) in the telmisartan group, 
as compared with 433 (4.3%) in the placebo group 
(hazard ratio, 1.10; 95% CI, 0.97 to 1.26). How-
ever, after 6 months, the number of such events 
was lower in the telmisartan group than in the 
placebo group, with 893 events (8.8%) and 1030 
events (10.1%), respectively (hazard ratio, 0.87; 
95% CI, 0.80 to 0.95; P = 0.004 for interaction 
between the two periods). Adjustment for post-
randomization differences in blood pressure did 
not materially affect the estimated treatment ef-
fects of telmisartan for stroke, either overall 
(hazard ratio, 0.96; 95% CI, 0.87 to 1.05) or at 
more than 6 months (hazard ratio, 0.89; 95% CI, 
0.79 to 1.00), or for major cardiovascular events, 
either overall (hazard ratio, 0.94; 95% CI, 0.87 to 
1.01) or at more than 6 months (hazard ratio, 0.88; 
95% CI, 0.81 to 0.96).
The number of patients who had new-onset 
diabetes after randomization was 125 (1.2%) in the 
telmisartan group, as compared with 151 (1.5%) 
in the placebo group (hazard ratio, 0.82; 95% CI, 
0.65 to 1.04; P = 0.10) (Fig. 2B and Table 3).
Other Outcomes
There were no significant differences between 
the telmisartan group and the placebo group in 
the number of patients who died (755 vs. 740), had 
a major hemorrhage (385 vs. 399), had migraine 
in the first 6 months (429 vs. 447), or had head-
ache in the first 7 days (2006 vs. 2102). The num-
ber of patients who had intracranial bleeding did 
not differ significantly between the telmisartan 
group (112 patients) and the placebo group (138 
patients) (1.1% vs. 1.4%; hazard ratio, 0.81; 95% 
CI, 0.63 to 1.05).
Subgroup Analyses
In prespecified subgroups of patients, results for 
stroke (Fig. 3A) and for major cardiovascular 
events (Fig. 3B) indicated no heterogeneity of ef-
fects. Separate analyses of patients who underwent 
early randomization (<10 days after a stroke) 
showed results similar to those in the entire study 
cohort. At 30 days in this subgroup, there was no 
significant increase in risk in the telmisartan 
group, as compared with the placebo group, for 
stroke (51 patients vs. 44 patients) or for major car-
diovascular events (72 patients vs. 56 patients).
Table 2. Selected Adverse Events Leading to Discontinuation of a Study Drug. 
Adverse Event
Telmisartan
(N = 10,146)
Placebo
(N = 10,186) P Value
no. (%)
Total 1450 (14.3) 1127 (11.1) <0.001
Hypotensive symptoms 393 (3.9) 186 (1.8) <0.001
Syncope 21 (0.2) 6 (0.1) 0.004
Uncontrolled hypertension 13 (0.1) 17 (0.2) 0.47
Headache 231 (2.3) 203 (2.0) 0.16
Diarrhea 69 (0.7) 45 (0.4) 0.02
Nausea 104 (1.0) 72 (0.7) 0.01
Vomiting 74 (0.7) 61 (0.6) 0.25
Angioedema 23 (0.2) 31 (0.3) 0.28
Renal impairment 28 (0.3) 18 (0.2) 0.14
Hyperkalemia 14 (0.1) 6 (0.1) 0.07
Atrial fibrillation 81 (0.8) 50 (0.5) 0.006
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Discussion
In our study, we compared telmisartan with pla-
cebo initiated soon after an ischemic stroke, with 
patient follow-up for an average of 2.5 years. We 
showed that telmisartan did not significantly re-
duce the risk of a subsequent stroke, of the com-
posite outcome of major cardiovascular events, 
or of new-onset diabetes.
Elevated blood pressure after a stroke is as-
sociated with recurrent events, and long-term 
lowering of blood pressure reduced recurrent 
strokes in the PROGRESS study.3 At first glance, 
the data from our trial may appear to be discrep-
ant with those from the PROGRESS trial. However, 
there are several differences between the studies. 
First, at baseline, patients’ mean blood pres-
sure was higher in the PROGRESS study (147/86 
mm Hg) than in our study (144/84 mm Hg). Sec-
ond, a majority of patients (58%) in the PROGRESS 
study were assigned to receive a combination of 
perindopril plus indapamide, which reduced blood 
pressure to a substantial degree (12.3/5.0 mm Hg), 
as compared with those receiving an ACE inhibi-
tor only, for whom the blood pressure reduction 
was more modest (4.9/2.8 mm Hg). The reduction 
of stroke in the PROGRESS study was seen large-
ly among patients receiving combination therapy. 
The smaller reduction in blood pressure in our 
study and the lower initial blood pressure levels 
may in part explain the apparent differences in 
the results.
The results of our analysis were unaltered after 
accounting for the modest reduction in blood 
pressure in the telmisartan group. This finding 
raises the question of whether agents that block 
the renin–angiotensin system offer additional ben-
efit independent of their effects on blood pres-
sure. In both the HOPE study5,6 and the Losartan 
Intervention for End-point Reduction in Hyper-
tension (LIFE) study (ClinicalTrials.gov number, 
NCT00338260),10 it was suggested that such 
mechanisms may be important. However, in the 
PROGRESS trial, a clear reduction in the risk of 
stroke was observed only in the group that re-
ceived a combination of perindopril plus a di-
uretic, which reduced systolic blood pressure by 
12 mm Hg. No significant reduction in the risk 
of stroke occurred in patients receiving perindo-
pril alone, which reduced systolic blood pressure 
by a more modest 5 mm Hg.3 The role of ARBs 
is currently being further evaluated in two large 
trials with expected mean follow-ups of more 
than 4 years.11,12
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Figure 1. Kaplan–Meier Curves of the Cumulative Probability of Recurrent Stroke (Primary Outcome).
During a mean follow-up of 2.5 years, 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the 
placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% CI, 0.86 to 1.04; P = 0.23). 
Hazard ratios were calculated with the use of the Cox model, which was adjusted for baseline age, use of angio-
tensin-converting–enzyme inhibitors, diabetes status, and modified Rankin Scale score. 
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Post hoc exploratory analyses suggested that 
there was no significant difference in event rates 
in the first 6 months after randomization for the 
primary outcome and for two of the secondary 
outcomes, with a difference emerging later. These 
findings, while provisional, suggest that the effect 
of telmisartan in our study was time dependent. 
In the HOPE and PROGRESS trials, there was little 
or no apparent benefit in the first 6 months, 
whereas there was a gradual and continuing low-
ering in the rates of stroke and major cardiovas-
cular events thereafter. If this interpretation is 
correct, then the mean duration of follow-up in 
our study (2.5 years), which was shorter than that 
of the HOPE study (4.5 years) and the PROGRESS 
study (4 years), may have contributed to the lack 
of significant benefit associated with telmisar-
tan in our study.
We cannot rule out the possibility that telmi-
sartan therapy is associated with a modest increase 
in risk during the first 6 months of treatment. 
Patients in our study were treated, on average, 
earlier after their index stroke than in other trials 
(a median of 15 days, as compared with a median 
of 8 months in the PROGRESS study). Mildly 
elevated blood pressure in the acute post-stroke 
period may be associated with a more favorable 
outcome, perhaps because it preserves perfusion 
to ischemic regions.13,14 However, in the Acute 
Candesartan Cilexetil Therapy in Stroke Survivors 
(ACCESS) study,8 in which treatment with an ARB 
was initiated within the first few days after a 
stroke, an early benefit was reported. Further sub-
division of our data to focus only on patients who 
were treated very soon after a stroke (≤10 days) 
did not suggest a concentration of harm during 
the first 30 days of the study.
In our analysis, there was a nonsignificant 
trend toward a lower rate of new-onset diabetes 
associated with telmisartan. Several previous tri-
als have suggested that ACE inhibitors and ARBs 
can reduce the risk of diabetes,15,16 although no 
Table 3. Effect of Telmisartan on Primary, Secondary, and Selected Tertiary Outcomes.
Outcome
Telmisartan
(N = 10,146)
Placebo
(N = 10,186)
Hazard Ratio
(95% CI)* P Value
no. (%)
Primary
Recurrent stroke† 880 (8.7) 934 (9.2) 0.95 (0.86–1.04) 0.23
Ischemic 774 (7.6) 811 (8.0)
Hemorrhagic 59 (0.6) 69 (0.7)
Other or unknown 47 (0.5) 54 (0.5)
Secondary
Death from cardiovascular causes, recurrent stroke, myocardial 
infarction, or new or worsening heart failure
1367 (13.5) 1463 (14.4) 0.94 (0.87–1.01) 0.11
Death from cardiovascular causes‡ 223 (2.2) 263 (2.6)
Recurrent stroke‡ 855 (8.4) 914 (9.0)
Myocardial infarction‡ 168 (1.7) 169 (1.7)
New or worsening heart failure‡ 121 (1.2) 117 (1.1)
New-onset diabetes 125 (1.2) 151 (1.5) 0.82 (0.65–1.04) 0.10
Tertiary
Death from cardiovascular causes, recurrent stroke, or myocar-
dial  infarction§
1289 (12.7) 1377 (13.5) 0.94 (0.87–1.02) 0.13
Death from any cause  755 (7.4) 740 (7.3) 1.03 (0.93–1.14) 0.55
Death from cardiovascular causes or recurrent stroke¶ 1171 (11.5) 1249 (12.3) 0.94 (0.87–1.02) 0.15
* Hazard ratios are for patients in the telmisartan group, as compared with the placebo group. 
† Numbers are based on the incidence of the first recurrent stroke.
‡ This event was the first that occurred in the composite outcome.
§ This composite was included for direct comparison with results from the Heart Outcomes Prevention Evaluation (HOPE) trial.
¶ This outcome was a post hoc composite.
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significant benefit was shown in the only large 
randomized trial in which diabetes was the pri-
mary outcome.17
Our trial had a few limitations. First, the 
adherence to the telmisartan regimen was lower 
than that in other large trials of telmisartan, 
such as the Ongoing Telmisartan Alone and in 
Combination with Ramipril Global End-point Tri-
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Major Cardiovascular Events
New-Onset Diabetes
Figure 2. Kaplan–Meier Curves of the Cumulative Probability of a Major Cardiovascular Event or New-Onset Diabe-
tes (Secondary Outcome).
A composite of major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarc-
tion, or new or worsening heart failure) occurred in 1367 patients (13.5%) in the telmisartan group and 1463 pa-
tients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P = 0.11) (Panel A). Hazard ratios were 
calculated with the use of the Cox model, which was adjusted for baseline age, use of angiotensin-converting– 
enzyme inhibitors, diabetes status, and modified Rankin Scale score. New-onset diabetes occurred in 125 of 7306 
patients patients (1.7%) in the telmisartan group nd 151 of 7283 pati nts (2.1%) in the placebo group (hazard ra-
tio, 0.82; 95% CI, 0.65 to 1.04; P = 0.10) (Panel B). 
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Figure 3. Effect of Telmisartan on the Risk of Stroke or Major Cardiovascular Events in Prespecified Subgroups.
Shown are the effects telmisartan on the risks of stroke (Panel A) and major cardiovascular events (Panel B) in pre-
specified subgroups and in patients who underwent randomization either 10 days or less after the qualifying stroke 
or more than 10 days after the qualifying stroke. The sizes of the squares are proportional to the numbers of events. 
For details on calculation of the stroke risk score, see the Supplementary Appendix. 
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al (ONTARGET; NCT00153101).18 This may have 
been due in part to the absence of a run-in pe-
riod in our study and to the fact that most pa-
tients who had headache caused by aspirin plus 
extended-release dipyridamole stopped both sets 
of blinded medications in the factorial design. 
Second, in our study, more patients in the placebo 
group than in the telmisartan group received non-
study blood-pressure-lowering medications (in-
cluding ACE inhibitors), consistent with the pro-
tocol, which strongly emphasized blood-pressure 
control for all enrolled patients. These factors 
substantially minimized the difference in blood 
pressure between the telmisartan group and the 
placebo group by about one third and may also 
have contributed to a lack of a significant reduc-
tion in events. Third (as discussed above), the dura-
tion of the trial may have been too short.
In conclusion, we showed that the addition of 
ARB therapy to the use of other antihypertensive 
drugs soon after a stroke and continuing for a 
mean of 2.5 years did not significantly reduce the 
risk of subsequent stroke, major cardiovascular 
events, or new-onset diabetes.
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